1. Introduction {#s0005}
===============

Alzheimer\'s disease (AD) is characterized clinically by impaired cognitive function ([@bb0045]) and neuropathologically by extracellular amyloid-beta (Aβ) plaques, intracellular neurofibrillary tangles of hyper-phosphorylated tau protein, and synaptic/neuronal loss resulting in regional hypometabolism and cortical atrophy ([@bb0125]). To facilitate clinical diagnosis and early disease detection, several positron emission tomography (PET) radioligands were developed for imaging Aβ pathology in vivo, including ^11^C-radiolabelled Pittsburgh Compound B (\[C-11\]PiB) ([@bb0085]; [@bb0030]), ^18^F-Florbetapir ([@bb0195]), ^18^F-Flutemetamol ([@bb0190]), and ^18^F-florbetaben ([@bb0155]), the latter three of which have been FDA approved for clinical use ([@bb0070]). Although these Aβ PET radioligands have high affinity for fibrillary Aβ aggregates in the grey matter (GM), characterization of their sensitivity and specificity is ongoing.

One important tool in this ongoing characterization is the comparison of in vivo Aβ PET measures with postmortem measures of Aβ deposition commonly held to be the "gold standard" ([@bb0005]; [@bb0060]; [@bb0015]; [@bb0010]; [@bb0075]; [@bb0175]; [@bb0080]; [@bb0065]; [@bb0020]; [@bb0170]). These comparisons typically result in good, but imperfect, correlations between the in vivo and postmortem quantifications. This could be due to differences between what is actually detected by the in vivo PET Aβ tracers and the postmortem detection techniques, or it could be due to artifacts introduced by either the in vivo or postmortem analysis methods. Since most postmortem analyses quantify Aβ in microscopic fields limited only to brain cortex, one possible in vivo artifact could be created by the inclusion of tissues outside of the cortex caused by the relatively low spatial resolution of PET. This study looks at the effect of common methods to correct for this unintentional inclusion of non-cortical tissue in PET measurements of Aβ.

The poor spatial resolution of Aβ PET imaging relative to magnetic resonance (MR) imaging and X-ray computed tomography (CT) is due to technical factors including detector size, positron range, and noncollinearity ([@bb0160]). The spatial resolution of PET characterized by a point spread function (PSF) corresponds to the image of a point source and is modeled as a Gaussian function with a defined full width at half maximum (FWHM). Whole-body PET scanner spatial resolutions typically range from 4 mm to 6 mm FWHM. Quantification of radioactivity concentration in structures which are large in comparison to this resolution scale (\>2xFWHM) is reasonably accurate ([@bb0055]). However, in PET brain imaging, volume of interest (VOI) size typically falls below this threshold resulting in reduced measurement accuracy due to the blurring of activity between regions, i.e. activity spill-in/spill-out between adjacent VOIs. Resolution-induced inaccuracy is often referred to as the partial volume effect (PVE) ([@bb0055]; [@bb0100]). PVEs may confound quantification of Aβ PET imaging, particularly in elderly subjects where cortical atrophy, with the expansion of CSF spaces and thinning of cortex, may result in the underestimation of tracer uptake in CSF-bordering cortical grey matter (GM). Furthermore, non-specific white matter (WM) uptake (common to all currently available Aβ PET radioligands) can cross-contaminate cortical GM, potentially inflating the signal in Aβ-free healthy controls or reducing apparent retention signal in AD patients with high Aβ burden.

To address PVEs, several protocols were developed with variable success; these are referred to as partial volume correction (PVC) techniques and include: 1) the Meltzer method, which addresses spill-out of activity from the brain to CSF space but does not account for heterogeneity within tissue ([@bb0110]; [@bb0115]; [@bb0130]; [@bb0090]); 2) the modified Müller-Gärtner (mMG) method, which addresses cross-contamination between GM and WM but does not account for heterogeneity within WM or GM ([@bb0145]); 3) the geometric transform matrix (GTM) method ([@bb0150]); and 4) the Region-Based Voxel-Wise (RBV) method ([@bb0185]). The latter two methods account for within-tissue type heterogeneity through parcellating the brain into contiguous non-overlapping regions. Each of these methods rely on anatomical information typically provided by a co-registered MR image, and model the observed PET image as a convolution of the true image by a point spread function.

The impact of PVC techniques in Aβ PET studies is an ongoing area of investigation. [@bb0120] demonstrated that voxel-based analysis with the mMG method improved separation of AD and healthy control groups. [@bb0135] obtained similar results using the Meltzer method in their study of healthy controls, early-onset AD, and late-onset AD. However, [@bb0025] observed that when the mMG method was used, differences in \[C-11\]PiB PET uptake between semantic dementia and AD groups were less prominent. Recently, [@bb0180] demonstrated that PVEs, if uncorrected, can lead to underestimated measures of longitudinal change in Aβ pathology in the presence of decreasing cortical thickness. [@bb0165] observed that the use of Meltzer PVC increased longitudinal plausibility, that is the percent of subjects not decreasing in \[C-11\]PiB retention between baseline to follow-up scans. However, another study examining the regional correlations between \[C-11\]PiB and post-mortem Aβ pathology found correlations were consistent between uncorrected and mMG partial volume-corrected SUVR data ([@bb0170]).

In our investigations of the correspondence between \[C-11\]PiB PET and postmortem measures of Aβ pathology, we previously applied a modified form of the Meltzer PVC method to \[C-11\]PiB PET measures in two case reports ([@bb0060]; [@bb0065]), but uncorrected \[C-11\]PiB measures were not examined. In the current work, we compared the effects of three PVC techniques on the correspondence between region-matched in vivo PET and postmortem measures of Aβ pathology in nine subjects who had an in vivo \[C-11\]PiB PET scan and later underwent postmortem neuropathology examination.

2. Materials and methods {#s0010}
========================

2.1. Subject data {#s0015}
-----------------

Nine subjects (*n* = 6 male, *n* = 3 female) with in vivo \[C-11\]PiB PET and MR scans and postmortem histological assessments of Aβ pathology were included in this study ([Table 1](#t0005){ref-type="table"}). One case has been reported previously ([@bb0065]) (Case\#02). Clinical diagnosis of AD was based on a standardized University of Pittsburgh Alzheimer\'s Disease Research Center (ADRC) evaluation at a Consensus Conference, utilizing Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer\'s Disease and Related Disorders Association (NINCDS/ADRDA) criteria ([@bb0105]). Neuropathological diagnosis was determined by a board-certified neuropathologist (RLH or JKK) using Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) ([@bb0125]) and National Institute on Aging-Reagan Institute (NIA-RI) consensus ([@bb0140]) criteria ([Table 1](#t0005){ref-type="table"}).Table 1Demographics for nine subjects with postmortem measures of Aβ pathology load and in vivo \[C-11\]PiB PET and MR scans. Clinical diagnoses include probable Alzheimer\'s disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and normal cognition (NC), and were determined through a battery of tests including the Mini Mental State Exam (MMSE).Table 1SubjectDiagnosisGenderAge at scan (years)MMSE at scanPET-death interval (months)\[C-11\]PiB PET scan durationMR scanner & sequenceCase\#01ADMale581842.30--90 minGE Signa 1.5 T SPGRCase\#02DLBMale771017.20--90 minGE Signa 1.5 T SPGRCase\#03ADMale541930.40--90 minGE Signa 1.5 T SPGRCase\#04ADMale742110.50--90 minGE Signa 1.5 T SPGRCase\#05ADFemale662134.60--90 minGE Signa 1.5 T SPGRCase\#06FTDMale80737.20--90 minGE Signa 1.5 T SPGRCase\#07ADFemale792545.50--90 minGE Signa 1.5 T SPGRCase\#08NCFemale802831.840--70 minGE Signa 1.5 T SPGRCase\#09NCMale852937.440--70 minSiemens Tim Trio 3 T MPRG

Based on the last in vivo clinical diagnosis at time of scan, five subjects had probable AD, one subject had dementia with Lewy Bodies (DLB), one subject had frontotemporal dementia (FTD), and two subjects had normal cognition (NC). At the time of \[C-11\]PiB PET scan, Mini-Mental State Examination (MMSE) scores in the study cohort ranged from 29 to 7 and age ranged from 54 years to 85 years. The mean interval from time of scan to death was 31.9 ± 11.4 months (see [Table 1](#t0005){ref-type="table"}).

2.2. \[C-11\]PiB PET and MR imaging {#s0020}
-----------------------------------

All subjects underwent \[C-11\]PiB PET and MR imaging prior to death (see [Table 1](#t0005){ref-type="table"} for imaging details). Subjects received a spoiled gradient recalled MR scan (1.5 T, GE Signa) (*n* = 8) or a magnetization prepared rapid gradient echo MR scan (3 T, Siemens Tim Trio) (*n* = 1) for anatomic VOI definition and PVC tissue segmentation guidance. PET data were acquired as previously described ([@bb0130]; [@bb0090]) using a Siemens/CTI ECAT HR+ scanner (3-dimensional mode, 63 image planes, 15.2 cm field of view) following slow bolus injection of 14.9 ± 1.7 kBq of high specific activity (\>21.4 GBq/μmol) \[C-11\]PiB. PET emission data were acquired over 0--90 min (34 frames, *n* = 7) or 40--70 min (6 frames, *n* = 2) post injection. PET data were corrected for attenuation, scatter, and radioactivity decay, and reconstructed using the Direct Fourier (DIFT) method, similar to filtered backprojection, with a 3 mm Hann filter into a 128 × 128 × 63 matrix with voxel sizes of 2.06 × 2.06 × 2.43 mm^3^. The reconstructed PET image resolution was approximately 6 mm FWHM in the transverse and axial planes, measured using a point source phantom imaged in the center of the PET scanner field of view (FOV).

2.3. Brain autopsy and dissection {#s0025}
---------------------------------

This study was approved by the University of Pittsburgh Institutional Review Board and the University of Pittsburgh\'s Committee for Oversight of Research and Clinical Training Involving Decedents. Written informed consent for research and autopsy was obtained for all subjects in the study. Brain autopsies were performed under a University of Pittsburgh Alzheimer\'s Disease Research Center protocol, as previously described ([@bb0060]; [@bb0065]). For each case, the left cerebral hemisphere was immersed in 10% buffered formalin for 21 days, and then sliced into 1-cm thick axial blocks. CERAD designated brain regions were sampled for diagnostic purposes.

To quantify regional plaque load in the precuneus, tissue sections were dissected from 10% formalin-fixed axial tissue blocks and processed for histology and immunohistochemistry as described below.

2.4. Histology and immunohistochemistry {#s0030}
---------------------------------------

Histofluorescent labeling with 6-CN-PiB (10 μM), a highly fluorescent derivative of \[C-11\]PiB ([@bb0060]; [@bb0095]), and immunohistochemistry with 4G8, an antibody recognizing aa17-24 of Aβ ([@bb0065]), in the precuneus were performed using previously published protocols ([@bb0060]). Aβ pathology load (percent area of GM occupied by 6-CN-PiB-labeled or 4G8-immunoreactive Aβ deposits) was quantified using NIH Image (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, MD, USA, [http://rsb.info.nih.gov/ij/](http://rsb.info.nih.gov/ij){#ir0005}, 1997--2017) on three pairs of 40 μm-thick adjacent tissue sections equally spaced through the VOI tissue block as previously described ([@bb0065]). Additional adjacent tissue sections were processed using cresyl violet to delineate the boundary between GM and WM.

2.5. Volume of interest (VOI) matching in PET and postmortem tissues {#s0035}
--------------------------------------------------------------------

Matching of the autopsy precuneus VOI tissue block to the VOI sampling of the dynamic PET image data in the same region was based on a previously described method ([@bb0060]). VOI-labeled photographs of axial autopsy blocks guided VOI generation on the in vivo full-resolution axial MR image. Each subject\'s MR image was manually reoriented to match the orientation of the autopsy slice photograph, and VOIs were generated on these reoriented MR images to match those on the autopsy tissue. Adjustments to VOI placement on MR images were necessary due to postmortem collapsing of the ventricles after drainage of cerebral spinal fluid (CSF) and due to tissue deformation during fixation (see [Fig. 1](#f0005){ref-type="fig"}).Fig. 1Snapshot of precuneus VOI matching between post-mortem axial tissue block and matching in vivo MR image for Case\#07. From left-to-right, (A) is the post-mortem autopsy tissue block with excised region boxed, (B) is the in vivo MR image with VOI hand-drawn to match that in the autopsy photo, and (C) is the \[C-11\]PiB SUVR image with the hand-drawn VOI overlaid.Fig. 1

Frame-to-frame motion within dynamic PET images was visually assessed by applying a contour to a mid-time point frame delineating the pial surface and ventricles of the brain in ROITool software (CTI PET Systems Knoxville, TN, USA). If interframe motion was observed, a set of stable frames was averaged and used as reference for frame-to-frame registration using automated techniques previously described ([@bb0130]). After motion assessment, each subject\'s dynamic PET image was coregistered to the reoriented MR image using automated methods, and VOI maps were transferred from MR image to PET ([@bb0130]). A standardized uptake value (SUV) 50--70 min parametric image was then generated from the co-registered PET by averaging activity over the appropriate time frames on a voxel basis, then multiplying by the subject\'s weight and dividing by injected dose.

2.6. Partial volume correction application and sampling {#s0040}
-------------------------------------------------------

Each subject\'s reoriented MR image was parcellated using FreeSurfer v5.3 ([@bb0035]; [@bb0040]). Each FreeSurfer parcellation was visually inspected and manually edited to ensure GM, WM, CSF, and within-tissue anatomical boundaries were followed. Parcellations were combined into 86 anatomical regions and converted to binary masks. These 86 contiguous, non-overlapping binary masks spanned the entire brain and consisted of lateralized cortical and subcortical GM regions, cerebral WM, cerebellar GM, cerebellar WM, and brainstem. The binary masks were also combined to create full GM and WM tissue masks, both of which in turn were combined to create a single whole-brain tissue mask ([Fig. 2](#f0010){ref-type="fig"}B, C).Fig. 2Case\#01 MR scan and FreeSurfer segmentations and parcellations. (A) Case\#01 MR scan. (B) Case\#01 tissue binary mask (red) for use in Meltzer PVC. (C) Case\#01 GM binary mask (light blue) and WM binary mask (red) for use in mMG PVC. (D) Case\#01 total FreeSurfer parcellation with the hand-drawn precuneus GM VOI (pink) inserted for use in RBV PVC. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2

For each subject, a voxel-level Meltzer-corrected \[C-11\]PiB SUV image was generated from the subject\'s \[C-11\]PiB SUV parametric image and the whole-brain tissue mask, as described by [@bb0110]. A voxel-level mMG-corrected SUV image was generated from the SUV parametric image and the GM and WM tissue masks ([@bb0145]).

The autopsy-based precuneus VOIs were also incorporated into the contiguous, non-overlapping 86 binary masks. Any subregion generated by the intersection of an autopsy-based VOI and binary mask was excluded from the binary mask and treated as a new, separate binary mask. This FreeSurfer- and autopsy-derived binary mask parcellation of the brain ([Fig. 2](#f0010){ref-type="fig"}D) was used to generate a voxel-level RBV-corrected \[C-11\]PiB SUV image ([@bb0185]).

Each subject\'s autopsy-based VOIs were segmented into GM and WM portions using the FreeSurfer-derived GM and WM binary masks. The four SUV parametric images for each subject (not PV-corrected, Meltzer-corrected, mMG-corrected, and RBV-corrected) were then sampled using GM-only VOIs to mimic the Aβ pathology load analysis, which was assessed exclusively in the GM of each tissue block. For each subject, standardized uptake value ratios (SUVR) were produced by normalizing the VOI SUV to the equivalently corrected or uncorrected SUV value of the FreeSurfer-delineated cerebellar GM.

2.7. Statistical analyses {#s0045}
-------------------------

Precuneus regional correlation between in vivo \[C-11\]PiB SUVR and both postmortem 6-CN-PiB positive Aβ pathology load (percent area) and 4G8-immunolabeled Aβ pathology load (percent area) across all subjects was evaluated using Pearson\'s correlation coefficient. Statistical significance was set at *p* \< 0.01 (two-sided).

3. Results {#s0050}
==========

3.1. \[C-11\]PiB PET outcome measures {#s0055}
-------------------------------------

[Fig. 3](#f0015){ref-type="fig"} shows mean SUVR values for the precuneus region across all subjects and the three PVC techniques. On average, the Meltzer PVC method increased precuneus SUVR values by 14.2%. SUVR values were increased to a greater extent using the mMG method (44.8%) and the RBV PVC method (42.9%). PVC increased measured SUVR in all subjects, with the exception of Case\#07, which had small reductions in SUVR (1.7%) after correction with the Meltzer method, and Case\#08, where SUVR reductions ranged from 12.3%--13.9% for both mMG and RBV methods. The largest increases in SUVR due to PVC also occurred in Case\#07 (87.4% increase from mMG PVC) and Case\#01 (82.6% increase from RBV PVC).Fig. 3Mean precuneus SUVR values across subjects and partial volume correction methods. On average, the Meltzer PVC method increased precuneus SUVR values by 14.6%. The mMG and RBV methods increased SUVR values on average by 46.2% and 44.3%, respectively.Fig. 3

3.2. Correlations between in vivo \[C-11\]PiB PET and postmortem Aβ load {#s0060}
------------------------------------------------------------------------

Postmortem measures of Aβ pathology load (percent area) using 6-CN-PiB and 4G8 across all subjects in the study were highly correlated at *p* \< 0.01 ([Fig. 4](#f0020){ref-type="fig"}).Fig. 4Correlation between precuneus postmortem Aβ pathology measures using 4G8 percent area and 6-CN-PiB percent area. 4G8 and 6-CN-PiB are well correlated in this sample (Pearson *r* = 0.89, *p* \< 0.01).Fig. 4

Correlations between postmortem 6-CN-PiB Aβ pathology load (percent area) and in vivo SUVR measures are shown in [Fig. 5](#f0025){ref-type="fig"}. All partial volume correction methods minimally reduced the correlation between 6-CN-PiB and SUVR, but all correlations remain statistically significant at *p* \< 0.01. 6-CN-PiB measures for the precuneus ranged from 0.25% area (Case\#02, DLB) to 10.46% area (Case\#07, AD).Fig. 5Correlations between precuneus \[C-11\]PiB SUVR and 6-CN-PiB positive Aβ pathology (percent area) across subjects. Each point is labeled with the subject\'s case number. All correlations are statistically significant at *p* \< 0.01.Fig. 5

Correlations between postmortem 4G8-immunoreactive Aβ pathology load (percent area) and in vivo \[C-11\]PiB SUVR for the precuneus were similarly ranked across PVC techniques, with no PVC resulting in the highest correlation to 4G8-immunoreactive Aβ pathology load ([Fig. 6](#f0030){ref-type="fig"}). Again however, all correlations were statistically significant at *p* \< 0.01. 4G8 measures ranged from 0.86% area (Case\#08) to 14.02% area (Case\#01).Fig. 6Correlations between precuneus \[C-11\]PiB SUVR and 4G8-immunoreactive Aβ pathology (percent area) across subjects. Each point is labeled with the subject\'s case number. All correlations are statistically significant at *p* \< 0.01.Fig. 6

4. Discussion {#s0065}
=============

In this work, we examined the impact of three PVC techniques on \[C-11\]PiB PET measures and the correlation of \[C-11\]PiB PET measures with postmortem Aβ pathology load.

Averaged over subjects, the use of the Meltzer PVC technique resulted in approximately a 14% increase in precuneus SUVR values, consistent with a previously reported \~22% increased average \[C-11\]PiB uptake using the same method in a study of late-onset AD ([@bb0135]). Both the mMG and RBV correction methods in this work resulted in 44.8% to 42.9% increased precuneus SUVR values, similar to 44% (mMG corrected) and 56% (RBV corrected) increases observed in a previous study of AD subjects ([@bb0185]). Although previous studies have generally reported increases in \[C-11\]PiB retention measures after PVC ([@bb0185]; [@bb0120]; [@bb0135]; [@bb0180]), we observed reduced precuneus \[C-11\]PiB SUVR in two subjects. Application of the Meltzer method resulted in small decreases in precuneus SUVR in Case\#07 (AD), while the use of both mMG and RBV correction methods resulted in relatively large reductions in precuneus SUVR in Case\#08 (NC). In the first case, the Meltzer method had a larger impact on the cerebellar reference region than the precuneus SUV measure, increasing cerebellar GM SUV by 25%, slightly higher than the 22--23% increases in the precuneus SUV. A similar phenomenon was reported by [@bb0180] ([@bb0180]), who observed that the Meltzer correction method resulted in increased cerebellar cortex intensities but lower putamen binding potential values in specific subjects. In the current study, substantial cerebellar atrophy was apparent in the MR image for Case\#07, which likely led to the larger increase in cerebellar SUV and therefore lower precuneus SUVR.

The reductions in precuneus SUVR values for Case\#08 after both mMG- and RBV-correction are likely due to this case being a normal control subject with low specific binding of \[C-11\]PiB in GM. Non-specific signal from WM was relatively greater and likely spilled over into the precuneus GM voxels. Both the mMG and RBV methods correct for the partial volume effect from WM, so activity assumed to originate from WM is removed from GM voxels in the VOI, resulting in lower GM activity.

Collectively, these cases highlight the fact that the impact of any PVC technique is highly region- and subject-specific. MR image segmentation or parcellation, PET-to-MR image coregistration, and VOI placement must all be performed consistently and cautiously when applying any PVC technique in Aβ PET imaging, given the differing levels of atrophy and variable GM-to-WM binding ratios.

Despite having varied effects on \[C-11\]PiB PET SUVR in this small and diverse sample of subjects, the PVC techniques examined ranked similarly in their impact on correlations to 6-CN-PiB and to 4G8 measures of Aβ pathology load. This is expected given the strong correlation between 6-CN-PiB and 4G8 percent area coverage. Each PVC method resulted in minimally reduced correlations relative to no PVC, with RBV correction being the greatest, followed by mMG and Meltzer. Nevertheless, PET-to-postmortem correlations across all PVC methods and no PVC remained highly statistically significant at *p* \< 0.01. These results agree with [@bb0170], who also found that Müller-Gärtner correction had minimal impact on correlations between \[C-11\]PiB PET and postmortem measures of Aβ pathology load ([@bb0170]), and suggest the utility of PVC in Aβ PET imaging is application-specific and should continue to be examined. While previous studies have found PVC may be advantageous in discriminating diagnostic groups ([@bb0120]; [@bb0135]) or tracking longitudinal change ([@bb0180]; [@bb0165]), our results suggest PVC is of minimal importance in understanding the relationship between Aβ PET and Aβ pathology.

One limitation of this study is the small sample size. Additional subjects could significantly change PET-to-postmortem correlations, and the impact of PVC on correlations should be examined in a larger cohort. The inconsistent time intervals between PET scan and autopsy in this population is also a potential source of variability, as Aβ pathology may have accumulated beyond a subject\'s last \[C-11\]PiB PET scan, particularly in the clinically mild-moderate AD subjects examined in this study. Inaccuracies in tissue matching between postmortem excisions and VOIs on MR images, a particularly difficult task given the deformations brains undergo at autopsy as evidenced in [Fig. 1](#f0005){ref-type="fig"}, could contribute further variability. Finally, each of the PVC methods applied here are also susceptible to errors in PET-to-MR image registration and segmentation ([@bb0115]; [@bb0050]). Despite these limitations and potential sources of error, correlations between \[C-11\]PiB PET SUVR and both 6-CN-PiB percent area and 4G8 percent area were highly statistically significant with and without partial volume correction in this study.

5. Conclusions {#s0070}
==============

The Meltzer, modified Müller-Gärtner, and Region-Based Voxel-Wise partial volume correction techniques each had minimal impact on the correlation between \[C-11\]PiB PET SUVR and postmortem measures of Aβ pathology load, resulting in statistically insignificant reductions in PET-to-postmortem correlations. Thus, the utility of PVC should continue to be explored and questioned on an application-specific basis.
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